MONSANTO MTC UNIT SEES OPERATING LOSS IN NEW YORK April Monsanto Corp s G D Searle and Co unit said it will report an operating loss for mainly due to expenses for research and development Searle chairman Sheldon Gilgore said Searle s operating loss in will be less than the mln dlr operating loss in He said Searle s first quarter sales will be up pct to mln dlrs from mln dlrs in the year ago quarter In Searle s sales were mln dlrs Gilgore said the company intends to have sales of three billion dlrs by the mid s He said the company anticipates approval in Japan the U S Italy Spain and the U K for its ulcer treatment drug Cytotech He also said that in a paper not yet published the drug was shown to prevent a flare up of ulcers for a longer period of time than Tagamet made by SmithKline Beckman Corp SKB Other drugs in Searle s pipeline include tissue plasminogen activator TPA made by a different process than Genentech s GENE TPA expected to be approved for marketing this year Reuter